Navigation Links
Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
Date:12/6/2007

ssure that the necessary audio applications are downloaded and installed. These programs can be obtained at no charge to the user.

A replay of the call will be available two hours after the completion of the call at (888) 286-8010 in the U.S., ((617) 801-6888 for international callers), pass code 74113063. The replay will be available through Monday, December 24, 2007.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) as a single agent in small cell lung cancer, with temozolomide in brain tumors, and with hematopoietic cell transplantion in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding t
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 The Brandeis Medical Center, led by Dr. Emmanuel ... and affordable laser tattoo removal experience with the advanced Astanza Duality ... providing high quality cosmetic services with cutting edge medical technology and ... Southern California has seen a dramatic increase in the ...
(Date:1/14/2014)... Emergency Critical Care, a LifeCentre partner practice, located at 165 Fort ... first in Loudoun County to receive a ... M. Barnes , Medical Director, is a well-seasoned veterinarian of more ... , are avid scuba divers. "As altitude skiers and hikers, we ...
(Date:1/14/2014)... , Jan. 14, 2014   Oligomerix, Inc. , a ... therapeutics for Alzheimer,s disease (AD) and related neurodegenerative disorders, ... Valhalla, NY as of January ... space at New York Medical College. Oligomerix, ...
Breaking Medicine Technology:Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Sevocity, a division of Conceptual MindWorks, Inc. (CMI), today ... as a preferred electronic health record (EHR) vendor with ... leading true Internet or cloud-based EHR. This enables Sevocity ... health record system with low start-up cost and affordable ...
... STAMFORD, Conn., July 20, 2011 A new online ... healthcare professionals, law enforcement, and community organizations combat the ... Purdue Pharma L.P . has developed RxSafetyMatters.org ... company and organizations with which it is partnering to ...
Cached Medicine Technology:Sevocity® Named Preferred EHR Vendor by CITIA-SC, South Carolina's Health IT Regional Extension Center (REC) 2New Online Resource to Help Combat Abuse of Prescription Medications Launched by Purdue Pharma L.P. 2New Online Resource to Help Combat Abuse of Prescription Medications Launched by Purdue Pharma L.P. 3
(Date:4/23/2014)... that proliferation of endogenous neural precursor cells cannot ... axons. From the perspective of neural plasticity, Dr. ... in China observed the effects of functional electrical ... and expression of basic fibroblast growth factor and ... the infarct side. The researchers found that functional ...
(Date:4/22/2014)... sport in the United States with 1 million participants ... Center for Injury Research and Policy at Nationwide Children,s ... occurrence and distribution patterns of basketball-related injuries treated in ... among adolescents and teens. , The study, published online ... data relating to adolescents 13-19 years of age who ...
(Date:4/22/2014)... A recently FDA-approved device has been shown to reduce ... as 50 percent. When coupled with an innovative electrode ... device facilitated the complete elimination of seizures in nearly ... decade-long clinical trials. , That,s good news for a ... U.S. living with epilepsy whose seizures can,t be controlled ...
(Date:4/22/2014)... can provide primary care for low-income patients may ... insurance companies while improving patient health, researchers have ... that health clinics that avoid costs associated with ... lowering hospital admission rates and emergency room visits, ... State Altoona. , The researchers estimated that ...
(Date:4/22/2014)... are small cell lung cancers (SCLC), which grow ... researchers at Virginia Commonwealth University Massey Cancer Center ... to this resistance that may lead to improved ... B-cell lymphoma 2 (Bcl-2) family proteins, which are ... function, this family of proteins can trigger a ...
Breaking Medicine News(10 mins):Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2
... in Making Fatherhood Happen, ATLANTA, June 10 ... had 149,919 new babies born in 2005,the latest year ... many thousands of new mothers, there also were thousands ... becoming a father for the first time," said,fertility expert ...
... antimicrobial coated wristbands helps ... enhance safety, VERNON HILLS, Ill., June 10 ... delivering on-demand,specialty printing solutions for the healthcare industry, has ... printing,easier and more cost-effective for healthcare organizations., "Missing ...
... Researchers are harnessing the powers of digital communications ... the side-effects caused by chemotherapy. , They have ... phones on which the patients can record and send ... managing their care. The phones are capable of giving ...
... London, UK: For Dan Savage, surviving testicular cancer has been ... taking more adventurous decisions, and he says, that in retrospect, it ... him. But as he approaches the end of his fifth year ... as "cured" by the medical profession, he worries that from now ...
... discovered a new way to reduce neuronal loss in the ... loss in people with Alzheimer,s disease can be attributed to ... neuro-toxin Amyloid beta the major component of amyloid plaques ... a specific population of nerve cells in the basal forebrain. ...
... People with irritable bowel syndrome have a higher than usual ... study published tomorrow (Wednesday 11 June). , The research, ... new therapies for the estimated one in five UK adults ... is poorly understood. Symptoms of IBS include abdominal pain, bloating, ...
Cached Medicine News:Health News:Thinking About Being a Father? 2Health News:Zebra Technologies Introduces HC100(TM) Patient I.D. Wristbanding Solution 2Health News:Zebra Technologies Introduces HC100(TM) Patient I.D. Wristbanding Solution 3Health News:Managing symptoms by mobile phone may revolutionize cancer care for young people 2Health News:Managing symptoms by mobile phone may revolutionize cancer care for young people 3Health News:'Cancer was one of the best things to happen to me... but I worry about the future' 2Health News:QBI neuroscientists make Alzheimer's disease advance 2Health News:Common bowel problem linked to chili pepper pain receptor 2
... System is designed to help physicians provide ... leg. Endovenous laser therapy is a patient-friendly ... of varicose veins., In endovenous laser therapy, ... the varicosed vein, generally through a small ...
ELVeS is a new minimally-invasive laser treatment for patients with superficial vein reflux of the greater saphenous vein. The ELVeS laser treatment offers your patients an effective out-patient alt...
Using proven 1064 nm technology for the treatment of deeper lesions, the Lumenis One Multi-Spot Nd:YAG module provides versatility allowing targeted treatment of leg veins, vascular lesions, facial w...
... #1 physician choice in laser treatment, brings ... superficial vein reflux. EVLT is a minimally ... stripping that effectively and safely treats varicose ... occlude the vein. The procedure is easy ...
Medicine Products: